Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07729137Phase 2Not Yet Recruiting

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Role: lead

NCT05587205Phase 1Recruiting

Safety and Tolerability of EO2002

Role: collaborator

NCT05636579Phase 1Recruiting

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

Role: collaborator

NCT04894110Phase 1Completed

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

Role: lead

NCT04191629Phase 1Unknown

Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema

Role: collaborator

All 5 trials loaded